Viral Infections Vaccines & Prevention Public Health

Hepatitis C elimination a 'political commitment challenge'

Share

Clinical Scorecard: Hepatitis C elimination a 'political commitment challenge'

At a Glance

Category

Detail

Condition

Hepatitis C infection and efforts toward elimination

Key Mechanisms

Prevention, testing, linkage to care and curative antiviral treatment; transmission reduction through sterile injection equipment, opioid substitution therapy and other harm-reduction measures

Target Population

People with hepatitis C, including people who inject drugs, incarcerated people, pregnant people, children and men with HIV who have sex with men

Care Setting

Health systems, hospitals, emergency departments, correctional settings and community-based services

Key Highlights

  • World Health Organization estimates cited at the session indicated approximately 47 million people with hepatitis C worldwide, about 20% fewer than in 2015. Incidence declined about 8% and deaths about 12%, short of the respective 2030 reduction goals of 90% and 65%.

  • Approximately 68% of U.S. patients with hepatitis C had been diagnosed and 43% of diagnosed patients had received treatment, compared with 2030 targets of 90% and 80%.

  • In OPPORTUNI-C, treatment initiation within six months reached 85.7% with hospital-based assessment and treatment or care as soon as possible after discharge, versus 46.1% with usual outpatient referral.

  • In DETECT Hep C, nontargeted emergency-department screening produced a 34% higher diagnosis rate than targeted screening, but substantial losses occurred before linkage to care.

  • Speakers emphasized domestic financing, integration into existing services, simplified care pathways and addressing confirmatory testing costs.

Guideline-Based Recommendations

The supplied article reports speaker recommendations and selected study findings rather than a complete clinical guideline.

Diagnosis

  • Dr. Terrault highlighted emergency departments as an entry point for diagnosis, while emphasizing that diagnosis alone does not ensure treatment.

  • Dr. Trooskin described routine opt-out screening in correctional settings.

  • She described hepatitis C RNA testing at ages two to six months for perinatally exposed infants and emphasized at least annual hepatitis C testing for sexually active adolescents and adults among men with HIV who have sex with men.

Management

  • Treat acute hepatitis C upon confirmation without waiting for spontaneous clearance, as advised by Dr. Terrault.

  • Active substance use is not a contraindication to treatment, Dr. Trooskin emphasized. Encourage completion of all prescribed medication.

  • Integrate testing and treatment into services patients already use, supported by telehealth, community partnerships and specialist consultation.

  • For people who inject drugs, combine counseling, sterile injection equipment, opioid substitution therapy, testing and treatment.

  • Dr. Trooskin described approved direct-acting antiviral treatment for children ages three and older with chronic infection.

  • Treatment during pregnancy is not universally recommended but may be considered individually after discussion of potential risks and benefits.

Monitoring & Follow-up

  • Dr. Terrault emphasized lifelong liver cancer surveillance after cure for patients who had cirrhosis before treatment.

  • Patient tracking was a component of the Veterans Affairs approach.

  • Dr. Trooskin described linkage to care upon release from correctional settings.

Risks

  • Limited prevention services, financing and costly confirmatory virologic testing can impede elimination efforts.

  • Emergency-department diagnosis does not ensure linkage to treatment.

  • Dr. Terrault noted an association between metabolic dysfunction-associated steatotic liver disease and increased risk of liver complications after cure.

Patient & Prescribing Data

The Veterans Affairs system treated 80% of veterans with hepatitis C who were in care in 2021-2022, with sustained virologic response in more than 90% of those treated.

In HERO, per-protocol response rates exceeded 90%; intention-to-treat rates were lower. A separate analysis found response rates above 90% with medication adherence as low as 50%. Dr. Trooskin nevertheless encouraged completion of all prescribed medication.

An injectable glecaprevir/pibrentasvir formulation remained investigational, with findings reported in rats and human testing planned for 2027.

Clinical Best Practices

  • Make elimination a health-system priority and integrate testing and treatment into existing services.

  • Support access through multidisciplinary teams, telehealth, expanded prescribing capacity, integrated substance use care, patient tracking and financing.

  • Consider hospital-based assessment and treatment or care as soon as possible after discharge, as studied in OPPORTUNI-C.

  • Address confirmatory testing costs and barriers to treatment.

  • Connect screening with treatment and practical prevention services tailored to patients’ needs.

Related Resources & Content

  • Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial — Midgard H, Malme KB, Pihl CM, et al — Clinical Infectious Diseases — Published online November 22, 2023; 2024;78(3):582-590 — https://doi.org/10.1093/cid/ciad711. oup.silverchair-cdn.com

  • Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial — Haukoos J, Rothman RE, Galbraith JW, et al — JAMA — August 12, 2025;334(6):497-507 — https://doi.org/10.1001/jama.2025.10563. pubmed.ncbi.nlm.nih.gov

  • Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial — Litwin AH, Lum PJ, Taylor LE, et al; HERO Study Group — The Lancet Gastroenterology & Hepatology — December 2022;7(12):1112-1127 — https://doi.org/10.1016/S2468-1253(22)00275-8. clinicaltrials.gov

  • Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study — Heo M, Norton BL, Pericot-Valverde I, et al; HERO Study Group — Journal of Hepatology — Published online January 17, 2024; May 2024;80(5):702-713 — https://doi.org/10.1016/j.jhep.2023.12.020. pubmed.ncbi.nlm.nih.gov

  • The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada — Godin A, Kronfli N, Cox J, Alary M, Maheu-Giroux M — International Journal of Drug Policy — Published online April 8, 2020; February 2021;88:102738 — https://doi.org/10.1016/j.drugpo.2020.102738.